High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia

[1]  N. Chiorazzi,et al.  Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone. , 2003, Blood.

[2]  F. Mancini,et al.  Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. , 2003, Blood.

[3]  Adrian Wiestner,et al.  ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. , 2003, Blood.

[4]  Kevin R Coombes,et al.  High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. , 2003, Blood.

[5]  F. Vuillier,et al.  Chronic lymphocytic leukemia B cells expressing AID display dissociation between class switch recombination and somatic hypermutation. , 2003, Blood.

[6]  N. Kakazu,et al.  Constitutive Expression of AID Leads to Tumorigenesis , 2003, The Journal of experimental medicine.

[7]  W. Klapper,et al.  Expression of activation-induced cytidine deaminase in human B-cell non-Hodgkin lymphomas. , 2003, Blood.

[8]  N. Chiorazzi,et al.  Determining the clinical course and outcome in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.

[9]  Emili Montserrat,et al.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.

[10]  Arthur Weiss,et al.  Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. , 2002, Blood.

[11]  P. Casali,et al.  Ongoing In Vivo Immunoglobulin Class Switch DNA Recombination in Chronic Lymphocytic Leukemia B Cells1 , 2002, The Journal of Immunology.

[12]  Alberto Martin,et al.  Somatic hypermutation of the AID transgene in B and non-B cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. Oscier,et al.  Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. , 2002, Blood.

[14]  Axel Benner,et al.  Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. , 2002, Blood.

[15]  Göran Roos,et al.  Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. , 2002, Blood.

[16]  D. Oscier,et al.  CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. , 2002, Blood.

[17]  David Botstein,et al.  Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia , 2001, The Journal of experimental medicine.

[18]  C. Woo,et al.  Clonal instability of V region hypermutation in the Ramos Burkitt's lymphoma cell line. , 2001, International immunology.

[19]  H. Jacobs,et al.  Towards an understanding of somatic hypermutation. , 2001, Current opinion in immunology.

[20]  R. Rosenquist,et al.  CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. , 2001, Blood.

[21]  U. Jaeger,et al.  Association of CD38 Antigen Expression with Other Prognostic Parameters in Early Stages of Chronic Lymphocytic Leukemia , 2001, Leukemia & lymphoma.

[22]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[23]  T. Kipps.  Genetics of chronic lymphocytic leukaemia. , 2000, Hematology and cell therapy.

[24]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[25]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[26]  E. Thiel,et al.  Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. , 1999, Blood.

[27]  T. Kipps.  Chronic lymphocytic leukemia , 1997, Current opinion in hematology.

[28]  M. James,et al.  11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. , 1997, Blood.

[29]  E. Montserrat,et al.  Chronic lymphocytic leukemia. , 1995, The New England journal of medicine.

[30]  C. Gasche,et al.  Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Ciril Rozman,et al.  Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance , 1986, British journal of haematology.

[32]  J. Binet,et al.  A clinical staging system for chronic lymphocytic leukemia. Prognostic significance , 1977, Cancer.

[33]  L. Bullinger,et al.  Genetics of chronic lymphocytic leukemia: genomic aberrations and VH gene mutation status in pathogenesis and clinical course , 2002, Leukemia.

[34]  村松 正道.  Specific expression of activation-induced cytidine deaminase (AID) , a novel member of the RNA editing deaminase family in germinal center B cells , 1999 .

[35]  D C Case,et al.  Clinical staging of chronic lymphocytic leukemia. , 1977, The Journal of the Maine Medical Association.